Acadia Pharmaceuticals Licenses Saniona's SAN711 for $28 Million Upfront

MT Newswires Live

2024/11/27

Acadia Pharmaceuticals (ACAD) said Tuesday it will pay Saniona $28 million as part of an exclusive worldwide license agreement for the development and commercialization of SAN711 to treat rare neuropathic disorders and absence seizures.

Under the agreement, Acadia will also pay Saniona up to $582 million in milestone payments as well as tiered royalties.

Acadia said it will lead the development, regulatory and commercialization efforts of SAN711 and provide support for additional studies.

Price: 16.06, Change: -0.15, Percent Change: -0.93

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"澳洲华人首选美澳港股一站式交易平台 | 老虎证券","description":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","keywords":"老虎证券,老虎证券澳洲,老虎证券股票,老虎证券开户,老虎证券app,tigertrade老虎证券,股票,asx美股,炒股,券商,澳洲股票交易,澳大利亚炒股","social":{"ogDescription":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2486783078"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2486783078\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2486783078?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-27 06:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2486783078","market":"nz","top_or_hot":-1,"title":"Acadia Pharmaceuticals Licenses Saniona's SAN711 for $28 Million Upfront","media":"MT Newswires Live","content":"<html><body><p> Acadia Pharmaceuticals (ACAD) said Tuesday it will pay Saniona $28 million as part of an exclusive worldwide license agreement for the development and commercialization of SAN711 to treat rare neuropathic disorders and absence seizures.</p><p>Under the agreement, Acadia will also pay Saniona up to $582 million in milestone payments as well as tiered royalties.</p><p>Acadia said it will lead the development, regulatory and commercialization efforts of SAN711 and provide support for additional studies.</p><p>Price: 16.06, Change: -0.15, Percent Change: -0.93</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Acadia Pharmaceuticals Licenses Saniona's SAN711 for $28 Million Upfront</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAcadia Pharmaceuticals Licenses Saniona's SAN711 for $28 Million Upfront\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2024-11-27 06:08</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Acadia Pharmaceuticals (ACAD) said Tuesday it will pay Saniona $28 million as part of an exclusive worldwide license agreement for the development and commercialization of SAN711 to treat rare neuropathic disorders and absence seizures.</p><p>Under the agreement, Acadia will also pay Saniona up to $582 million in milestone payments as well as tiered royalties.</p><p>Acadia said it will lead the development, regulatory and commercialization efforts of SAN711 and provide support for additional studies.</p><p>Price: 16.06, Change: -0.15, Percent Change: -0.93</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2486783078","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2486783078","pubTimestamp":1732658892,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Acadia Pharmaceuticals  said Tuesday it will pay Saniona $28 million as part of an exclusive worldwide license agreement for the development and commercialization of SAN711 to treat rare neuropathic disorders and absence seizures.Under the agreement, Acadia will also pay Saniona up to $582 million in milestone payments as well as tiered royalties.Acadia said it will lead the development, regulatory and commercialization efforts of SAN711 and provide support for additional studies.Price: 16.06, Change: -0.15, Percent Change: -0.93","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","LU2065169927.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC","LU2065170008.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC","LU2065171402.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC","AKR":"阿卡迪亚房地产信托","BK4231":"零售房地产信托","BK4080":"零售业房地产投资信托","ACAD":"阿卡迪亚","LU2065171311.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) ACC"},"translate_title":"Acadia Pharmaceuticals预付2800万美元授权Saniona的SAN711","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AKR":1,"ACAD":0.9},"content_text":"Acadia Pharmaceuticals (ACAD) said Tuesday it will pay Saniona $28 million as part of an exclusive worldwide license agreement for the development and commercialization of SAN711 to treat rare neuropathic disorders and absence seizures.Under the agreement, Acadia will also pay Saniona up to $582 million in milestone payments as well as tiered royalties.Acadia said it will lead the development, regulatory and commercialization efforts of SAN711 and provide support for additional studies.Price: 16.06, Change: -0.15, Percent Change: -0.93","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}